EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Optimizing rhBMP-2 Therapy for Bone Regeneration: From Safety Concerns to Biomaterial-Guided Delivery Systems

Maria Chernysheva, Evgenii Ruchko iD, Artem Eremeev

International Journal of Molecular Sciences · 04.11.2025 · 26 (21) · 10723

DOI: 10.3390/ijms262110723 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.11.2025. Verfasst von Maria Chernysheva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, 119334 Moscow, Russia. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein 2, Bone Regeneration, Transforming Growth Factor beta, Biocompatible Materials. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government program of basic research in Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Government program of basic research at the Koltzov Institute of Developmental Biology of the Russian Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reconstruction of large and complex hard tissue defects remains a major clinical challenge, as conventional autografts and allografts are often limited in availability, biological compatibility, and long-term efficacy, particularly for extensive defects or poor bone quality. Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a potent osteoinductive factor capable of initiating the complete cascade of bone formation. However, its clinical use is restricted by dose-dependent complications such as inflammation, ectopic ossification, and osteolysis. This review synthesizes current evidence on the safety profile of rhBMP-2 and examines strategies to enhance its therapeutic index. Preclinical and clinical data indicate that conventional collagen-based carriers frequently cause rapid burst release and uncontrolled diffusion, aggravating adverse outcomes. It is noteworthy that low doses of rhBMP-2 (0.5–0.7 mg/level in anterior cervical discectomy and fusion (ACDF) or 0.5–1.0 mg/level in transforaminal lumbar interbody fusion (TLIF)) provide the optimal balance of efficacy and safety. Advanced biomaterial-based platforms, such as bioceramic–polymer composites, injectable hydrogels, and 3D-printed scaffolds, enable spatially and temporally controlled release while maintaining osteogenic efficacy. Molecular delivery approaches, including chemically modified messenger RNA (cmRNA) and regional gene therapy, provide transient, site-specific rhBMP-2 expression with reduced dosing and minimal systemic exposure. By integrating mechanistic insights with translational advances, this review outlines a framework for optimizing rhBMP-2-based regenerative protocols, emphasizing their potential role in multidisciplinary strategies for reconstructing complex hard tissue defects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Morphogenetic Protein 2Bone RegenerationTransforming Growth Factor betaBiocompatible MaterialsDrug Delivery SystemsHumansRecombinant ProteinsAnimalsOsteogenesis

Stichwörter der Autor:innen

biomaterial carriersbone regenerationgene therapyhard tissue reconstructionosteoinductionrhBMP-2

Substanzen

Bone Morphogenetic Protein 2Recombinant Proteinsrecombinant human bone morphogenetic protein-2Transforming Growth Factor betaBiocompatible Materials

Autor:innen und Institutionen

  • Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, 119334 Moscow, Russia.
  • Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.

ORCID-Profile: Evgenii Ruchko

Förderung

  • Government program of basic research in Koltzov Institute of Developmental Biology of the Russian Academy of Sciences
  • Government program of basic research at the Koltzov Institute of Developmental Biology of the Russian Academy of Sciences

Zitieren

APA

Chernysheva, M., Ruchko, E., & Eremeev, A. (2025). Optimizing rhBMP-2 Therapy for Bone Regeneration: From Safety Concerns to Biomaterial-Guided Delivery Systems. International Journal of Molecular Sciences, 26(21), 10723. https://doi.org/10.3390/ijms262110723

Vancouver

Chernysheva M, Ruchko E, Eremeev A. Optimizing rhBMP-2 Therapy for Bone Regeneration: From Safety Concerns to Biomaterial-Guided Delivery Systems. International Journal of Molecular Sciences. 2025;26(21):10723. doi:10.3390/ijms262110723

BibTeX
@article{Chernysheva2025,
  author = {Chernysheva, Maria and Ruchko, Evgenii and Eremeev, Artem},
  title = {Optimizing rhBMP-2 Therapy for Bone Regeneration: From Safety Concerns to Biomaterial-Guided Delivery Systems},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {21},
  pages = {10723},
  doi = {10.3390/ijms262110723}
}
Kostenlos starten →